---
document_datetime: 2024-11-21 11:02:30
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zubsolv-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zubsolv-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.4969829
conversion_datetime: 2025-12-22 11:18:28.724403
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zubsolv

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IB/0026              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 20/11/2024                          | n/a                                         |                                  |                                                                                                                        |
| PSUSA/2113/ 202309   | Periodic Safety Update EU Single assessment - buprenorphine / naloxone                                                                        | 30/05/2024                          | 26/07/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                              |            |            |                                  | PSUSA/2113/202309.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------|
| IA/0024   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 18/10/2023 | n/a        |                                  |                      |
| IAIN/0023 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                   | 05/10/2023 | 26/07/2024 | Annex II and PL                  |                      |
| IB/0021   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 04/09/2023 | 26/07/2024 | SmPC and PL                      |                      |
| IA/0022   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                 | 27/06/2023 | n/a        |                                  |                      |
| IA/0020   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                   | 24/04/2023 | n/a        |                                  |                      |
| R/0019    | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 19/05/2022 | 27/07/2022 | SmPC, Annex II, Labelling and PL |                      |

<div style=\"page-break-after: always\"></div>

| IB/0018/G   | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished non-significant in-process test                                                                                                                                                                  | 28/01/2022   | n/a        |             | product - Deletion of a   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------|
| IAIN/0017/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites manufacturer for batch release) | 18/01/2022   | n/a        |             | (excluding                |
| II/0015     | B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                                                                                                                                                                                            | 02/09/2021   | n/a        |             |                           |
| IAIN/0016   | To update section 4.4 of the SmPC and section 2 of the PL to include sleep-related breathing disorders. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the                                                                                                                                                                                                                          | 07/06/2021   | 27/07/2022 | SmPC and PL |                           |

<div style=\"page-break-after: always\"></div>

|           | assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0014    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/03/2021 | 22/03/2021 | SmPC, Labelling and PL |
| IB/0013   | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                                                                 | 22/12/2020 | n/a        |                        |
| IB/0012   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                 | 22/12/2020 | n/a        |                        |
| IB/0011   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                           | 22/12/2020 | 22/03/2021 | SmPC                   |
| IA/0010/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.7 - Administrative change - Deletion of manufacturing sites | 04/12/2020 | n/a        |                        |
| IAIN/0009 | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/09/2020 | 22/03/2021 | SmPC and PL            |

<div style=\"page-break-after: always\"></div>

|                    | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2113/ 201909 | Periodic Safety Update EU Single assessment - buprenorphine / naloxone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/05/2020 | n/a | PRAC Recommendation - maintenance |
| IB/0007            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/02/2020 | n/a |                                   |
| IAIN/0006          | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/07/2019 | n/a |                                   |
| IAIN/0005/G        | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 31/05/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| T/0004    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/03/2019   | 17/04/2019   | SmPC, Labelling and PL   |                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------|
| T/0003    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/11/2018   | 17/12/2018   | SmPC, Labelling and PL   |                   |
| IB/0002/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- products | 02/05/2018   | n/a          |                          | sterile medicinal |
| IB/0001/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished                                                                                                                                                                                                                                                                                          | 02/02/2018   | 17/12/2018   | SmPC, Labelling and PL   |                   |

<div style=\"page-break-after: always\"></div>

product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished

<div style=\"page-break-after: always\"></div>

| product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|